Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB06-036 Multiple Ascending Doses in Chronic Hepatitis B
NCT05828745Phase 1Completed
- Sponsor
- Zhimeng Biopharma
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of cb06-036 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Zhimeng Biopharma. Primary endpoint: Safety and Tolerability of CB06-036. Started Apr 2024; status: completed.
02
Drugs
cb06-036
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05828745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828745.